The sNDA is supported by data from the phase 3 ENERGIZE and ENERGIZE-T studies, which evaluated mitapivat vs placebo in patients with NTD and TD alpha- or beta-thalassemia, respectively.
The protocol most commonly used is the triple marker screen, which measures serum levels of alpha-fetoprotein (AFP), unconjugated estriol (uE3), and beta-human chorionic gonadotropin (beta-hCG).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback